Brought to you by 
Creative BioMolecules, Ontogeny, Reprogenesis merge
18 Jan 2001
Executive Summary
Creative BioMolecules (tissue regeneration) will acquire private developmental biology biotech Ontogeny and tissue-engineering company Reprogenesis to form a new company Curis--with cash reserves of $70mm--in which CBM will have a 43% position, Ontogeny a 38% stake, and Reprogenesis will hold 19%. For every three Curis shares, stockholders will receive ten CBM shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Creative BioMolecules, Ontogeny, Reprogenesis merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice